MedPath

Cortendo AB

🇸🇪Sweden
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.cortendo.com

Clinical Trials

35

Active:26
Completed:8

Trial Phases

2 Phases

Phase 1:29
Phase 3:6

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (35 trials with phase data)• Click on a phase to view related trials

Phase 1
29 (82.9%)
Phase 3
6 (17.1%)

Bioavailability of Levoketoconazole and Ketoconazole Tablets

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2019-12-26
Last Posted Date
2020-01-31
Lead Sponsor
Cortendo AB
Target Recruit Count
34
Registration Number
NCT04212000
Locations
🇺🇸

Pharmaceutical Research Associates, Inc., Salt Lake City, Utah, United States

Drug Interaction Study of Levoketoconazole and Metformin

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
First Posted Date
2019-03-19
Last Posted Date
2019-08-30
Lead Sponsor
Cortendo AB
Target Recruit Count
32
Registration Number
NCT03880825
Locations
🇺🇸

Clinical Pharmacology of Miami, LLC, Miami, Florida, United States

Levoketoconazole Food Effect Study in Healthy Subjects

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
First Posted Date
2018-12-07
Last Posted Date
2019-02-04
Lead Sponsor
Cortendo AB
Target Recruit Count
22
Registration Number
NCT03768388
Locations
🇺🇸

Clinical Pharmacology of Miami, LLC, Miami, Florida, United States

Open-label Treatment in Cushing's Syndrome

Phase 3
Completed
Conditions
Cushing Syndrome
Cushing Disease
Interventions
First Posted Date
2018-08-08
Last Posted Date
2025-06-19
Lead Sponsor
Cortendo AB
Target Recruit Count
51
Registration Number
NCT03621280
Locations
🇺🇸

The Center for Diabetes and Endocrine Care, Fort Lauderdale, Florida, United States

🇺🇸

Emory University, Atlanta, Georgia, United States

🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

and more 27 locations

A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.

Phase 3
Completed
Conditions
Endogenous Cushing's Syndrome
Interventions
First Posted Date
2017-09-11
Last Posted Date
2022-11-08
Lead Sponsor
Cortendo AB
Target Recruit Count
84
Registration Number
NCT03277690
Locations
🇺🇸

Keck Medical Center University of Southern California HCII, Internal Medicine - Keck Hospital, Los Angeles, California, United States

🇺🇸

Cedars-Sinai Medical Center, Cedars-Sinai Pituitary Center, Los Angeles, California, United States

🇺🇸

UCLA School of Medicine, Medicine/Endocrinology Department, Los Angeles, California, United States

and more 42 locations
  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.